These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36651168)

  • 1. The association between hepatic steatosis and incident cardiovascular disease, cancer, and all-cause mortality in a US multicohort study.
    Ahmed HS; Wang N; Carr JJ; Ding J; Terry JG; VanWagner LB; Hou L; Huo Y; Palmisano J; Zheng Y; Benjamin EJ; Long MT
    Hepatology; 2023 Jun; 77(6):2063-2072. PubMed ID: 36651168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic steatosis and cardiovascular disease outcomes: An analysis of the Framingham Heart Study.
    Mellinger JL; Pencina KM; Massaro JM; Hoffmann U; Seshadri S; Fox CS; O'Donnell CJ; Speliotes EK
    J Hepatol; 2015 Aug; 63(2):470-6. PubMed ID: 25776891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study.
    Long MT; Zhang X; Xu H; Liu CT; Corey KE; Chung RT; Loomba R; Benjamin EJ
    Hepatology; 2021 Feb; 73(2):548-559. PubMed ID: 33125745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal muscle mass and abdominal obesity are independent predictors of hepatic steatosis and interact to predict ten-year cardiovascular disease incidence: Data from the ATTICA cohort study.
    Kouvari M; Polyzos SA; Chrysohoou C; Skoumas J; Pitsavos CS; Panagiotakos DB; Mantzoros CS
    Clin Nutr; 2022 Jun; 41(6):1281-1289. PubMed ID: 35504171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remnant cholesterol, stronger than triglycerides, is associated with incident non-alcoholic fatty liver disease.
    Cheng Y; Zhang Q; Li H; Zhou G; Shi P; Zhang X; Guan L; Yan F; Xu C
    Front Endocrinol (Lausanne); 2023; 14():1098078. PubMed ID: 37214248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-invasive tools for liver steatosis and steatohepatitis predict incidence of diabetes, cardiovascular disease and mortality 20 years later: The ATTICA cohort study (2002-2022).
    Kouvari M; Chrysohoou C; Damigou E; Barkas F; Kravvariti E; Liberopoulos E; Tsioufis C; Sfikakis PP; Pitsavos C; Panagiotakos D; Mantzoros CS;
    Clin Nutr; 2024 Mar; 43(3):900-908. PubMed ID: 38387279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fat quality and incident cardiovascular disease, all-cause mortality, and cancer mortality.
    Rosenquist KJ; Massaro JM; Pedley A; Long MT; Kreger BE; Vasan RS; Murabito JM; Hoffmann U; Fox CS
    J Clin Endocrinol Metab; 2015 Jan; 100(1):227-34. PubMed ID: 25226289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relations of liver fat with prevalent and incident chronic kidney disease in the Framingham Heart Study: A secondary analysis.
    Wilechansky RM; Pedley A; Massaro JM; Hoffmann U; Benjamin EJ; Long MT
    Liver Int; 2019 Aug; 39(8):1535-1544. PubMed ID: 31033142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coffee consumption is not associated with prevalent subclinical cardiovascular disease (CVD) or the risk of CVD events, in nonalcoholic fatty liver disease: results from the multi-ethnic study of atherosclerosis.
    Simon TG; Trejo MEP; Zeb I; Frazier-Wood AC; McClelland RL; Chung RT; Budoff MJ
    Metabolism; 2017 Oct; 75():1-5. PubMed ID: 28964324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver Fat Is Associated With Markers of Inflammation and Oxidative Stress in Analysis of Data From the Framingham Heart Study.
    Fricker ZP; Pedley A; Massaro JM; Vasan RS; Hoffmann U; Benjamin EJ; Long MT
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1157-1164.e4. PubMed ID: 30476583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic Dysfunction-Associated Fatty Liver Disease Better Predicts Incident Cardiovascular Disease.
    Jeong S; Oh YH; Choi S; Chang J; Kim SM; Son JS; Lee G; Kim W; Park SM
    Gut Liver; 2022 Jul; 16(4):589-598. PubMed ID: 34730107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of diabetes on subclinical atherosclerosis and major cardiovascular events in individuals with and without non-alcoholic fatty liver disease.
    Wang B; Zhao Z; Liu S; Wang S; Chen Y; Xu Y; Xu M; Wang W; Ning G; Li M; Wang T; Bi Y
    Diabetes Res Clin Pract; 2021 Jul; 177():108873. PubMed ID: 34051282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease.
    Arvind A; Henson JB; Osganian SA; Nath C; Steinhagen LM; Memel ZN; Donovan A; Balogun O; Chung RT; Simon TG; Corey KE
    Hepatol Commun; 2022 Feb; 6(2):309-319. PubMed ID: 34558862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes.
    Mantovani A; Mingolla L; Rigolon R; Pichiri I; Cavalieri V; Zoppini G; Lippi G; Bonora E; Targher G
    Int J Cardiol; 2016 Dec; 225():387-391. PubMed ID: 27768965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular risk factors in non-alcoholic fatty liver disease.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Askling J; Hultcrantz R; Kechagias S
    Liver Int; 2019 Jan; 39(1):197-204. PubMed ID: 30253056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis.
    Mantovani A; Csermely A; Petracca G; Beatrice G; Corey KE; Simon TG; Byrne CD; Targher G
    Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):903-913. PubMed ID: 34555346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease: A post hoc analysis of a cohort study.
    Yoshitaka H; Hamaguchi M; Kojima T; Fukuda T; Ohbora A; Fukui M
    Medicine (Baltimore); 2017 May; 96(18):e6712. PubMed ID: 28471965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A simple clinical model predicts incident hepatic steatosis in a community-based cohort: The Framingham Heart Study.
    Long MT; Pedley A; Massaro JM; Hoffmann U; Ma J; Loomba R; Chung RT; Benjamin EJ
    Liver Int; 2018 Aug; 38(8):1495-1503. PubMed ID: 29377504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The associations between changes in hepatic steatosis and heart failure and mortality: a nationwide cohort study.
    Park J; Kim G; Kim H; Lee J; Jin SM; Kim JH
    Cardiovasc Diabetol; 2022 Dec; 21(1):287. PubMed ID: 36564787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Nonalcoholic Fatty Liver Disease With Lower Brain Volume in Healthy Middle-aged Adults in the Framingham Study.
    Weinstein G; Zelber-Sagi S; Preis SR; Beiser AS; DeCarli C; Speliotes EK; Satizabal CL; Vasan RS; Seshadri S
    JAMA Neurol; 2018 Jan; 75(1):97-104. PubMed ID: 29159396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.